Table 1.
Ongoing clinical trials to target myeloid-derived suppressor cells (MDSC) in cancer patients.
| No. | Title | Disease or conditions | Interventions | Trial number |
|---|---|---|---|---|
| 1 | MDSC and chronic myeloid leukemia | Chronic myeloid leukemia | Imatinib | NCT03214718 |
| 2 | Depletion of MDSC to enhance anti-PD-1 therapy | Non-small cell lung cancer (NSCLC), stage IIIB | Nivolumab | NCT03302247 |
| Nivolumab + Gemcitabine | ||||
| 3 | MDSC and checkpoint immune regulators’ expression in allogeneic SCT Using Flu-Bu-ATG | Leukemia, myelodysplastic syndromes | Fludarabine, Busulfan | NCT02916979 |
| Methotrexate | ||||
| 4 | MDSC control by signal regulatory protein-alpha: investigation in hepatocellular carcinoma | Hepatocellular carcinoma | Therapy-independent collection of human samples | NCT02868255 |
| 5 | Myeloid-derived suppressor cells clinical assay in finding kidney cancer | Metastatic and recurrent renal cell cancer | Computed tomography, cytology specimen collection, laboratory biomarker analysis, magnetic resonance imaging | NCT02664883 |
| 6 | Capecitabine + bevacizumab in patients with recurrent glioblastoma | Glioblastoma | Capecitabine | NCT02669173 |
| Bevacizumab | ||||
| 7 | Dendritic cell (DC) vaccine with or without gemcitabine. pre-treatment for adults and children with sarcoma | Sarcoma | Gemcitabine | NCT01803152 |
| Soft tissue sarcoma | ||||
| Bone sarcoma | DCs vaccine | |||
| 8 | SX-682 treatment in subjects with metastatic melanoma concurrently treated with pembrolizumab | Melanoma stage III | SX-682 | NCT03161431 |
| Melanoma stage IV | Pembrolizumab | |||
| 9 | PDE5 inhibition via tadalafil to enhance antitumor Mucin 1 vaccine efficacy in patients with HNSCC | Head and neck squamous cell carcinoma | Tadalafil | NCT02544880 |
| Anti-MUC1 vaccine | ||||
| Anti-influenza vaccine | ||||
| 10 | Phase II trial of EP4 receptor antagonist, AAT-007 (RQ-07; CJ-023,423) in advanced solid tumors | Prostate cancer | RQ-00000007 | NCT02538432 |
| NSCLC | ||||
| Breast cancer | Gemcitabine | |||
| 11 | MDSC clinical assay in finding and monitoring cancer cells in blood and urine samples from patients with or without localized or metastatic bladder cancer | Stage II bladder cancer | Cytology specimen collection procedure, laboratory biomarker analysis | NCT02735512 |
| Stage III bladder cancer | ||||
| 12 | RTA 408 capsules in patients with melanoma—REVEAL | Melanoma | Omaveloxolone | NCT02259231 |
| Unresectable (stage III) melanoma | Ipilimumab | |||
| Metastatic (stage IV) | Nivolumab | |||
| 13 | PDL-1 expression on circulating tumor cells in NSCLC | Lung cancer | Blood sample collection for CTC and MDSC analysis | NCT02827344 |
| 14 | Effect of Astragalus-based formula: Qingshu-Yiqi-Tang on modulating immune alterations in lung cancer patients | Non-small-cell lung carcinoma | Astagalus-based formula: Qingshu-Yiqi-Tang | NCT01802021 |
| 16 | A phase II trial of tadalafil in patients with squamous cell carcinoma of the upper aero-digestive tract | Head and neck squamous cell carcinoma | Tadalafil | NCT01697800 |
| 17 | Relevance of peripheral cells in the pathophysiology of chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia | Clinical data collection | NCT03280888 |
| 18 | Histamine receptor 2 antagonists as enhancers of antitumor immunity | Cancer | Ranitidine | NCT03145012 |
| 19 | Preoperative nutrition with immune enhancing nutritional supplement (immunomodulation) | Pancreatic adenocarcinoma | Dietary supplement: Nestle IMPACT advanced recovery and Nestle Boost high protein drink | NCT02838966 |
| 20 | A study of RGX-104 in patients with advanced solid malignancies and lymphoma | Malignant neoplasms | RGX-104 | NCT02922764 |
| 21 | Determination of immune phenotype in glioblastoma patients | Glioblastoma multiforme | Surgery | NCT02751138 |
| 22 | Academia Sinica Investigator Award 2010 | Breast cancer | Unknown | NCT01287468 |
| 23 | The “Fuzzing” therapy of TCM to improve the survival quality of early-stage NSCLC by intervening the CTCs | NSCLC | JinFuKang | NCT02603003 |
| Cisplatin | ||||
| Pemetrexed | ||||
| 24 | Antibody DS-8273a administered in combination with nivolumab in subjects with advanced colorectal cancer | Colorectal neoplasm | DS-8273a + nivolumab | NCT02991196 |
| 25 | Study to assess safety and immune response of stage IIB-IV resected melanoma after treatment with MAGE-A3 ASCI | Melanoma | recMAGE-A3 + AS15 ASCI | NCT01425749 |
| 26 | Potentiation of cetuximab by regulatory T cells depletion with CSA in advanced head and neck cancer | Head and neck squamous cell carcinoma | Cyclophosphamide | NCT01581970 |
| Cetuximab | ||||
| 27 | IMA970A plus CV8102 in very early, early and intermediate stage hepatocellular carcinoma patients | Hepatocellular carcinoma | IMA970A, CV8102, Cyclophosphamide | NCT03203005 |
| 28 | Intensive locoregional chemoimmunotherapy for recurrent ovarian cancer plus intranodal DC vaccines | Cancer of ovary | Cisplatin + celecoxib + DC vaccine, cisplatin + CKM + celecoxib + DC vaccine | NCT02432378 |
| 29 | Trial of SBRT with concurrent ipilimumab in metastatic melanoma | Melanoma | Stereotactic body radiotherapy, ipilimumab | NCT02406183 |
| 30 | Lenalidomide maintenance therapy for multiple myeloma | Multiple myeloma | Lenalidomide | NCT01675141 |
| 31 | Ipilimumab and all-trans retinoic acid combination treatment of stage IV melanoma | Melanoma | All-trans retinoic acid ipilimumab | NCT02403778 |
| 32 | Study evaluating the influence of LV5FU2 bevacizumab plus ANAKINRA Association on Metastatic Colorectal Cancer | Metastatic colorectal cancer | ANAKINRA | NCT02090101 |
| 33 | A phase I/Ib study of AZD9150 (ISIS-STAT3Rx) in patients with advanced/metastatic hepatocellular carcinoma | Advanced adult hepatocellular carcinoma | AZD9150 | NCT01839604 |
| Hepatocellular carcinoma metastatic | ||||
| 34 | AZD9150 with MEDI4736 in patients with advanced pancreatic, non-small lung and colorectal cancer | Malignant neoplasm of digestive organs intestinal tract; primary malignant neoplasm of respiratory and intrathoracic organ carcinoma | MEDI4736 | NCT02983578 |
| AZD9150 | ||||
| 35 | Study to assess MEDI4736 with either AZD9150 or AZD5069 in advanced solid tumors and relapsed metastatic squamous cell carcinoma of head and neck | Advanced solid tumors and metastatic squamous cell carcinoma of the head and neck | MEDI4736 | NCT02499328 |
| AZD9150 | ||||
| AZD5069 | ||||
| Tremelimumab | ||||